Table 2.
Distribution of PLH by their clinical status at government health institution in Bahir Dar, Ethiopia, 2016.
| Variable | Frequency | Percent | |
|---|---|---|---|
| name | (n = 400) | ||
| Recent CD4* count (cells/μl) | <500 cells/μl | 220 | 55 |
| Duration of HIV status | ≥500 cells/μl | 180 | 45 |
| known | <5 years | 220 | 55 |
| 5–10 years | 148 | 37 | |
| >10 years | 32 | 8 | |
| Duration on HAART* | <5 years | 207 | 51.7 |
| 5–10years | 177 | 44.3 | |
| >10 years | 16 | 4 | |
| Total daily pill burden | 2-Jan | 228 | 57 |
| >2 | 172 | 43 | |
| WHO HIV clinical staging | Stage I | 154 | 38.5 |
| Stage II | 159 | 39.8 | |
| Stage III/IV | 87 | 21.8 | |
| opportunistic infections | Yes | 105 | 26.3 |
| No | 295 | 73.8 | |
| Treatment regimen | First-line | 325 | 81.3 |
| Second line | 75 | 18.8 | |
| Comorbid medical diseases | Yes | 73 | 18.3 |
| Social Support | No | 327 | 81.8 |
| Poor | 84 | 21 | |
| Medium | 232 | 58 | |
| Adherence to HAAR | Strong | 84 | 21 |
| Poor | 70 | 17.5 | |
| Perceived stigma | Good | 330 | 82.5 |
| Yes | 185 | 46.3 | |
| No | 215 | 53.8 |
*
HAART- highly active antiretroviral therapy.
Cluster of differentiation 4 (CD4) levels.